Cayman Islands counsel to Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, in relation to its US$650 million public offering of ADSs and pre-funded warrants. Lucy Anderson led our team.
